Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3763-3771

  Lüth, Stefan ^a   Schrader, Jörg ^a   Zander, Stefan ^a   Carambia, Antonella ^a   Buchkremer, Juliane ^b   Huber, Samuel ^a   Reifenberg, Kurt ^c   Yamamura, Ken Ichi ^e   Schirmacher, Peter ^d   Lohse, Ansgar W ^a   Herkel, Johannes ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROTEIN P53;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CHEMICAL CARCINOGENESIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE ACTIVATION; GENE OVEREXPRESSION; GENOTOXICITY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER INJURY; LIVER REGENERATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HEPATOCYTES; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957922293     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3232     Document Type: Article

References (34)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
2. Seef LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006;25:3771-7. (Pubitemid 43980472)
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87. (Pubitemid 44286000)
4. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977-90. (Pubitemid 40884391)
5. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-32. (Pubitemid 46209851)
6. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al. TGF-b suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501. (Pubitemid 39370505)
7. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4. (Pubitemid 47056470)
8. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6. (Pubitemid 39329586)
9. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 2005;5:375-86.
10. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61. (Pubitemid 28293291)
11. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
12. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48. (Pubitemid 44631652)
13. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon-γ.J Exp Med 2002;196:129-34.
14. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117-28.
15. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001;19:378-87. (Pubitemid 32900080)
16. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35. (Pubitemid 32405812)
17. Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004;199:1701-7. (Pubitemid 38822003)
18. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, et al. IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006;203:1391-7. (Pubitemid 43877600)
19. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, et al. Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver. Proc Natl Acad Sci U S A 1994;91:614-8. (Pubitemid 24041452)
20. Wiegard C, Wolint P, Frenzel C, Cheruti U, Schmitt E, Oxenius A, et al. Defective T helper 1 response by hepatocyte-stimulated CD4 T cells impairs anti-viral CD8 response and viral clearance. Gastroenterology 2007;133:2010-8. (Pubitemid 350180810)
21. + regulatory T cells. Hepatology 2005;42:193-9.
22. Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon g. Hepatology 2005;41:906-15. (Pubitemid 40462953)
23. Kano A, Watanabe Y, Takeda N, Aizawa S, Akaike T. Analysis of IFN-γ-induced cell cycle arrest and cell death in hepatocytes. J Biochem 1997;121:677-83. (Pubitemid 27170850)
24. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 2004;279:5811-20. (Pubitemid 38220612)
25. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal 2007;19:454-65. (Pubitemid 46107818)
26. Levine AJ, Hu W, Feng Z. The p53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027-36.
27. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7. (Pubitemid 29428873)
28. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6;24-37. (Pubitemid 43053650)
29. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006;97:439-47. (Pubitemid 43811583)
30. Matsuda M, Nakamoto Y, Suzuki S, Kurata T, Kaneko S. Interferon-γ- mediated hepatocarcinogenesis in mice treated with diethylnitrosamine. Lab Invest 2005;85:655-63. (Pubitemid 40675446)
31. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Cancer Res 2008;68:8437-45.
32. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17:286-97.
33. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-9.
34. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007;13:1523-31. (Pubitemid 46450444)